Please select the option that best describes you:

Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?  

24 months ADT + abiraterone + definitive RT is indicated for cN1 disease but not for pN1 disease per NCCN. Can the data be extrapolated to this population? It seems preferable to indefinite ADT.

Answer from: Radiation Oncologist at Academic Institution